Biotech Century Therapeutics Inc. ipsx set terms for its initial public offering on Monday, with plans to offer 10.6 million shares priced at $18 to $20 each. The company has applied to list on Nasdaq, under the ticker symbol "IPSC." JP Morgan, BofA Securities, SVB Leerink and Piper Sandler are underwriting the deal. Proceeds will be used to fund pre-clinical activity and research and development, as well as working capital and general corporate purposes. "e are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need," the company says in its prospectus.